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Chemistry and pharmacological diversity of quinoxaline motifs 
as anticancer agents
Surpassing heart diseases, cancer is taking the lead as the 
deadliest disease because of its fast rate of spreading in all 
parts of the world. Tireless commitment to searching for 
novel therapeutic medicines is a worthwhile adventure in 
synthetic chemistry because of the drug resistance predica-
ment and regular outbreak of new diseases due to abnor-
mal cell growth and proliferation. Medicinal chemistry 
researchers and pharmacists have unveiled quinoxaline 
templates as precursors of importance and valuable inter-
mediates in drug discovery because they have been estab-
lished to possess diverse pharmacological potentials. 
Hence, this review highlights the current versatile routes to 
accessing functionalized quinoxaline motifs and harness-
ing their documented therapeutic potentials for anticancer 
drug development.
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INTRODUCTION
Cancer is a predicament that has received considerable attention as a top-rated killer 
disease, which is responsible for over 70 % cases of mortality in less developed countries. 
Based on the consistent rise in the statistical data on cancer related deaths, it has been 
forecast that 11.5 million deaths will be recorded by the year 2030 (1). Cancers mainly occur 
as a result of mutagenicity in the gene encoding DNA. This results in the abnormal cell 
trait leading to rapid spread of abnormal cells that destroy neighboring tissues and could 
quickly spread to other parts of the body (2). Outbreak of tumor-related multidrug resis-
tance (MDR) is a crucial reason for the widely reported failure rate in cancer therapy. The 
incidence of resistance among commercially available anticancer drugs has created more 
avenues for further quest for newer molecular entities for the therapeutic fight against 
cancer (3). The extra mass of tissues formed when cells are proliferating abnormally where 
they are not required are called tumors. They may be either benign or malignant, and the 
latter are cancerous and require disease control and prevention (4). According to molecular 
mechanisms, imidazolquinoxalines have been reported to show strong anticancer poten-
tial, which resulted from TNF-α production impairment through activation of p38MAPK 
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pathway and inhibition of PI3K pathway in the L929 murine fibroblast cell line (5). Thymi-
dine kinase 1 (TK1) and thymidine phosphorylase (TYMP) are key molecular targets of 
thymidine therapeutics in cancer treatment. Hence, cytosolic thymidine pathways have 
been documented to be a highly effective tool in the modulation of anticancer activity of a 
thymidine quinoxaline conjugate (6). In view of the adverse effect of this global phenom-
enon, various researchers have synthesized numerous nitrogen containing heterocyclic 
compounds as agents of transformation in anticancer motifs in the chemotherapeutic 
world. For instance, some commercially available anticancer heterocycles include benz-
imidazole-based nocodazole (7), quinazoline-based KYS05090 (8), pyrimidine-based 5-fluoro-
uracil and quinoline-based camptothecin (9).  
Over the years, heterocycles have been the largest areas of research in organic chem-
istry. Numerous biologically relevant compounds such as most of the phytochemicals and 
secondary metabolites as well as nucleotides contain heterocyclic rings. Quinoxaline falls 
into the class of benzodiazines and it has its heteroatomic nitrogen located at positions 1- 
and 4- of the heterocyclic nucleus (10). Latest information has unveiled quinoxaline nucle-
us as a privileged template among nitrogen-based heterocycles owing to its numerous 
valuable chemical properties (11), utilization in materials science research (12) and diverse 
pharmacological potentials (13). Hence, it is worthwhile targeting a review at quinoxaline 
as a dynamic heterocyclic compound to open more windows of opportunities among an-
ticancer drugs.
PHYSICAL PROPERTIES OF QUINOXALINE
Quinoxaline (also 1,4-benzodiazine, 1,4-diazinaphthalene, 1,4-naphthyridine, benzo-
paradiazine, C8H6N2, Mr 130.15) is a low melting solid. It melts at 29–32 oC just above room 
temperature. Its boiling point is 220–223 oC. It is weakly basic (pKa 0.60). It is miscible with 
water and has a density of 1.124 g mL–1 at 25 oC (14). Quinoxaline frameworks are fre-
quently reported to be from synthetic sources. Incorporation of at least one phenyl moiety 
in quinoxaline, as well as a structurally related heterocycle such as phenazine, increases 
the total number of resonance hybrids for such quinoxaline derivatives (4). 
OVERVIEW OF CANCER
Cancer could be described as a compounded disorder that could be traceable elemen-
tarily to an environmental phenomenon. Carcinogens have been reported to be encoun-
tered by people through their exposure to water, air, chemicals, sunlight and food (15). It 
is interesting to note that more than 90 % of cancers happen in the epithelia since epithe-
lial cells cover a significant part of the body such as skin, respiratory and alimentary tracts. 
They also play a crucial role in metabolizing the ingested carcinogens (16). Mutations of 
the protein-encoding genes which control cell division are often responsible for the dis-
crepancy and anomalies in cancer cells. This is because the proteins that are responsible 
for repairing worn-out cells and DNA damage are made by malfunctioning genes, which 
genes are also mutated. Treatment of cancer cells with DNA2 inhibitors recapitulates phe-
notypes observed upon DNA2 depletion, including reduced DNA double-strand break 
end resection and attenuation of HR repair. Similarly to genetic ablation of DNA2, chemi-
cal inhibition of DNA2 selectively attenuates the growth of various cancer cells with onco-
gene-induced replication stress (17).
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Inconsistent with the highly regulated physiological processes in normal cells, cancer 
cells undergo autonomous metabolic reprogramming to maintain rapid growth and pro-
liferation and escape from growth suppressors and cell death signaling. Numerous cell 
signaling pathways are implicated in the induction and maintenance of epithelial mesen-
chymal transition (EMT), such as TGF-beta, Wnt/beta-catenin, Notch and oncogenic Src or 
Ras signaling (18), and the zinc finger E-box binding homeobox (ZEB) family transcrip-
tional factors involved in the EMT processes are ZEB1 and ZEB2. Cancer is recognized by 
the uninhibited development of cells without differentiation caused by the de-regulation 
of proteins controlling cell division, cell multiplication and, also some critical enzymes 
(17). Recently, low protein diets have been reported to be associated with lowered cancer 
incidence and mortality risk of cancers in humans. In murine models, protein restriction 
inhibits tumor growth via the mTOR signaling pathway. IGF-1, amino acid metabolic pro-
graming, FGF21, and autophagy may also serve as potential mechanisms of protein re-
striction mediated cancer prevention (19). The dietary intervention aimed at reducing pro-
tein intake can be beneficial and has the potential to be widely adopted and effective in 
preventing and treating cancers (19). The beneficial role of low protein diets in tumor 
growth and cancer outcomes has been observed in numerous studies. For example, the 
result of a study showed a 70 % inhibition of tumor growth in the castrate-resistant Lu-
CaP23.1 prostate cancer model and a 56 % inhibition in the WHIM16 breast cancer model 
fed a 7 % protein diet when compared to an isocaloric 21 % protein diet (20).
Causes of cancer
There are diverse causes of cancer which are noted to be complicated in nature, com-
prising factors in the ecosystem and cells. Considerable attention has been directed to-
wards unveiling the major causes of cancer, some of which are herein underlined as to-
bacco smoke carcinogens, alcohol consumption, dietary factors, body mass and obesity, 
physical inactivity and inherited genetic abnormality.
Tobacco smoke carcinogens. – Statistical estimation has shown that cigarette consump-
tion is accountable for the annual mortality rate of over one million human beings via lung 
cancer and diverse other neoplasms. Mutation loads are usually greater with  an excess of 
G to T transversions among cancers traceable to smoking, which in turn results in higher 
frequency of p53 mutations (2). According to a recent study, the  risk of conditional breast 
cancer specific death rate was on the increase amidst female population with recurring 
smoking habits compared to women that never smoke (21, 22).
Alcohol consumption. – It has been asserted that alcohol consumption plays a crucial 
role in the recent drastic increase in cancer cases (23, 24). According to the summary of a 
review, heavy alcohol consumption (more than four bottles per day) was significantly re-
lated to elevated risk of cancer associated with mouth and alimentary canals (24). Al-
though the biological mechanism is not yet fully understood, the report on an epidemio-
logical study supports the verdict which says high alcoholic consumption causes cancerous 
cells manifestation in seven crucial parts of the human body (25). A study on drinking and 
health risk clearly showed that the risk of death from liver diseases caused by alcohol 
consumption skyrocketed (Fig. 1) after consumption of a couple of drinks per day (26).
Dietary factors. – People’s daily feeding habits have a direct impact on either averting 
or conferring risks. Improvement of daily fruit and vegetables intake cannot be overem-
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phasized in the promotion of a healthy diet in order to prevent and avert insurgence of 
abnormal cell proliferation, chronic diseases and various disorders (27). Total cholesterol, 
triglyceride levels and glycaemic load should be monitored and controlled in breast cancer 
risk populations because they may be associated with increased risk. High intake of poly-
phenol/phyto-oestrogen-rich food (i.e., flavonoids, soya products), as well as fibers, fruits 
and vegetables, may have potential protective effects against breast cancer occurrence but 
the results might vary according to hormonal status (28).
Evidence of the relationship between dietary habits and cardiovascular disorder risks 
among the middle-aged population and elderly persons has been reported in literature 
(28). Factors contributing to the reduction of cardiovascular disease and cancer incidence 
would contribute tremendously to improvements in health and longevity (29).
Body mass and obesity. – Body mass and obesity provide estimated statistics of roughly 
twenty percent of documented cancerous cell issues (30). Excess body mass might have a 
direct or indirect effect on cancer risk in some ways. Surplus body fat may have a direct 
impact on the immune system dependent factors, inflammation and the amount of some 
hormonessuch as insulin and estrogen. It can also affect factors that control cell growth 
and hormonal regulatory proteins that regulate effective utilization of such hormones by 
the body system (31). Weight gain in already diagnosed breast cancer patients was re-
ported to increase the risk, while weight loss might reduce the risk (32). 
Physical inactivity. – Improvement in the quality of life of subjects after the diagnosis 
of breast cancer (33) and bladder cancer (34) was documented to be directly related to 
physical activity (35). Life survival among the physically active  mature female population 
diagnosed with breast cancer could be efficiently improved by lower estrogen levels in 
such subjects; though there are insufficient data to support this hypothesis (36).
Inherited genetic abnormality. – There have been cases showing that genetic abnormality 
inherited by the subjects could be an underlying factor in many cancer cases. Most cancerous 
cells result from genetic structural changes due to a lack of control mechanisms respon-
sible for the prevention of cancerous cell development (37). The gene encoding portion of 
Fig. 1. Heavy alcohol consumption and the risk of selected cancers. Estimates for alcohol consump-
tion of 4 or more drinks per day vs. non/occasional drinkers, except for pancreatic (i.e., ≥ 3 drinks per 
day vs. non/occasional drinkers) and breast (i.e., ≥ 4.5 drinks per day vs. non-drinkers) cancers; SD 
bars, n = 3 (drawn based on raw data from ref. 24). CI – confidence interval.
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cancer was found to have the ability to cluster in families (38, 39). Cancers are considered 
to be hereditary in nature and are related to the sudden change in the appearance of inherited 
genes. Inherited breast cancers are known to occur earlier in life compared to sporadic 
types which are known to be non-inherited (40). Abnormalities in the cell cycle progres-
sion are caused by a disruption that resulted from the loss of functioning ability of tumor 
suppressor genes. Cancer is the crucial disease that the geneticists have been fighting against 
and is found to be hard to unveil at the molecular level. It is known to exist continuously 
in families (41).
Demographic data 
Information about the incidence of some common cancers across various regions of 
the world has been reported (42) and the results are shown in Table I.
Table I. Estimated age-standardized incidence and mortality rates per 100,000 subjects in different world areas
Continent Region
Incidence Mortality
Male Female Male Female
Africa
Eastern Africa 121.2 125.3 105.4 95.9
Central Africa 88.1 96.7 78.5 75.6
Northern Africa 109.2 98.9 89.5 68.2
Southern Africa 235.9 161.0 172.1 108.1
Western Africa 92.0 123.5 80.1 91.2
Asia
Eastern Asia 222.1 158.1 155.5 87.3
South-Central Asia 99.7 110.8 78.0 71.7
South-Eastern Asia 143.9 141.7 112.3 89.4
Western Asia 152.8 119.5 113.9 74.3
North America
Caribbean 196.3 153.5 116.6 86.2
Central America 136.2 134.4 84.7 80.6
North America 334.0 274.4 122.4 91.5
South America South America 186.7 162.9 116.6 88.2
Europe
Central and Eastern 
Europe 259.2 184.2 181.5 94.0
Northern Europe 292.3 249.5 134.6 99.7
Southern Europe 289.9 212.2 149.9 81.2
Western Europe 337.4 250.9 138.4 84.3
Australia
Australia/New Zealand 356.8 276.4 125.6 86.0
Melanesia 146.0 133.4 119.8 95.9
Micronesia 153.8 164.4 104.7 70.3
Polynesia 225.0 201.5 133.6 87.9
a Source: ref. 37.
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Overall cancer incidence and mortality rates by sex across the world are shown in 
Table I. The sample population used per region is 100,000. The incidence rate for both 
sexes combined is more than 3 times as high in Australia/New Zealand (633.2) as that in 
central Africa (184.8). It was noticed that the incidence was consistently higher in male 
than in female subjects in all regions of Asia, Europe and the Caribbean, except for South-
Central Asia where the incidence in females was higher than that in males by 11 ‰ (Table 
I). There is less regional variability in mortality than in incidence. Male mortality rate is 
higher than that of females in all African sub-regions except in Western Africa where the 
reverse was the case. Overall, the highest mortality rate for men was found in Central and 
Eastern Europe while that of women was highest in Southern Africa (42). Cancer cases 
have been decreasing in several western countries, largely owing to improved treatment 
and increased awareness and early detection; rates continue to increase in many countries 
with more limited resources and health infrastructure, particularly in Central and South 
America and Eastern Europe.
Breast cancer in females and lung cancer in males are the most frequently diagnosed 
cancers and the leading cause of cancer death for each sex in both economically developed 
and developing countries, while lung cancer is preceded by prostate cancer as the most 
frequent cancer among males in economically developed countries (42).
Types of cancer
Cancer has been categorized using various parameters of paramount importance. 
Some of the main types of cancer have been estimated based on the number of deaths. The 
most commontypes discussed in this study include lung cancer, leukemia, colorectal can-
cer, liver cancer and breast cancer. 
Lung cancer. – Lung cancer has been also referred to as pulmonary carcinoma. The 
highest factor that often results in lung cancer is smoking (43). It has been reported that the 
second hand smoking of radon and particulate matters related to air pollution agents such 
as benzene (44), formaldehyde (44) and diesel air pollutants (45) are other identified sources 
of lung cancer. The symptoms include consistent coughing, concise and interrupted 
breath, puffing sound, bloody spittle, continuous bronchitis and other chest pain related 
issues (46). Subjects with small cell lung cancer (SCLC) were reported to have stronger 
initial response to chemotherapy than those with non-small cell lung cancer (NSCLC) (47, 
48) although they are both responsible for eighty-five percent of lung cancer (47). 
Leukemia. – Leukemia originates from cells that are essential to new blood cell formation 
(49). Cells of these types are found in the bone marrow. Leukemia, having started in the soft 
inner parts of the bone, is then transported to other parts of the body through the blood 
stream (50). There are indications that any cell responsible for blood formation could change 
to leukemia. They can develop into one of the three main types of blood cells (51). Acute lym-
phocytic leukemia (ALL), also called acute lymphoblastic leukemia, progresses rapidly and if 
not treated could be fatal according to the findings of an earlier review (52). Some of the major 
causative agents of leukemia are the degree of exposure to radiation (53), exposure to hazard-
ous chemicals (54), viral infections (55), certain inherited syndromes. Treatments for leukemia 
include chemotherapy, radiation therapy, targeted therapy, stem cell transplant (56).
Colorectal cancer. – Colorectal cancer can be described as a type of cancer that origi-
nates from either the colon or the rectum (57, 58). It was unveiled by epidemiological studies 
183
O. O. Ajani et al.: Chemistry and pharmacological diversity of quinoxaline motifs as anticancer agents, Acta Pharm. 69 (2019) 177–196.
 
as the third most virulent class of cancer globally (59). Most colorectal cancers develop 
gradually over many years. Prior to the commencement of cancer development, a non-
-cancerous polyp on the inner wall of either colon or rectum often initiates tissue or tumor 
growth (60). There are certain risks that can cause this type of cancer. These include: the 
type of diet (eating meat cooked at high temperature might cause statistical odds of getting 
colorectal cancer), lack of physical exercise, obesity, smoking, high alcohol consumption, 
individual record of stomach inflammatory disease, genealogical record of colorectal cancer 
events, inherited syndromes (61) among others. Colorectal cancer has symptoms such as 
excessive blood loss through the rectum, mental exhaustion, weariness, fatigue, unwanted 
weight loss, hematochezia, cramps and abdominal pain (62). Prevention of colorectal cancer, 
primary or secondary (63), could involve screening of the population without symptoms 
of cancer or pre-cancer conditions (64).  
Liver cancer. – Liver cancer incidence is more rampant in developing countries (65). Cases 
of HBV and HCV were reported to be a crucial risk factor for liver cancer, also known as 
hepatocellular carcinoma (66). Among the human population in developing countries, intake 
of contaminated food items possessing mycotoxins, aflatoxin, along with active hepatitis 
virus infection constitutes a salient risk (67). In addition to these, excessive alcohol intake is 
also among odds for  liver cancer in industrialized nations of the world through the develop-
ment of cirrhosis and alcoholic hepatitis (68). The early stage of liver cancer can be treated by 
surgery; however, the removal of affected tissues via radiofrequency, chemo-embolization 
or alcohol insertion could be alternative treatments to surgery (1).
Breast cancer. – Breast cancer is a form of tumor with malignant traits that originates 
in breast cells (69). One of the ways in which breast cancer can spread is via the lymph 
system, which is a salient point to comprehend breast cancer (70). Most breast cancers are 
cancers that originate from the epithelial cells which shape breast tissues and are referred 
to as carcinomas (71). This cancer can also be transferred genetically. Women who started 
menstruating early have a higher chance of this menace, probably due to the long lasting 
period of exposure to progesterone and estrogen (71). Other risk factors are alcohol 
 consumption, physical inactivity. There are some steps that can be undertaken to reduce 
the risk. 
MALIGNANT TUMORS 
Formation and development of malignant tumors can start in cellular parts of any 
organ with a high tendency of involvement in replication. Tumors of epithelial tissue in-
clude sarcoma of soft tissues and bone, glioma (brain), leukemia and lymphoma (hemato-
poietic and lymphatic tissues). Carcinomas are the most frequent class (72). Cancer cells 
have the tendency to produce two types of tumors, either the non-cancerous (benign tu-
mors) or cancerous type (malignant tumors). Malignant tumors, generally categorized as 
carcinomas and sarcomas (73), can grow rapidly and harmfully, thereby destroying parts 
of tissues and organs in proximity to the tumor site (74).  
Progression of malignancy begins with mutation and proceeds through hyperplasia, 
dysplasia to in situ cancer and/or invasive cancer (75). A typical malignant tumor is malig-
nant mesothelioma; some of its symptoms are painful abdomen, inflammation or accumu-
lation of fluid in the abdomen, weight loss, nausea, vomiting and constipation. Reports 
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have also shown that these malignant mesotheliomas are more common in men than 
women (76). The best way malignant mesothelioma can be prevented is by limiting the 
exposure to asbestos at home, workplace or even public places (77). These tumors can be 
diagnosed early using various spectroscopic techniques (78).
QUINOXALINE – PRIVILEGED HETEROCYCLE
Owing to the privileged nature of functionalized quinoxaline heterocycle, quinoxa-
line-carbohydrate hybrids have been designed and evaluated as new and selective agents 
of impact in cytotoxic activity and photochemically induced cleaving in DNA (79). Quinox-
aline-based compound 1, coded as XK469, belongs to the class of quinoxalines with anti-
tumor efficiency and is structurally related to compound 2, commonly called chloroqui-
noxaline sulfonamide, CQS (NSC-339004). Quinoxaline-based compounds 1 and 2 are both 
known as antineoplastic quinoxaline topoisomerase II inhibitors (80). Quinoxaline 1,4-di-
N-oxides (QdNOs) have manifold biological properties. Recent development of QdNOs, 3, 
4 and 5, which are non-toxic until they are activated in the hypoxic cell, opens a new era 
in anticancer drug discovery (81). Numerous quinoxaline frameworks are currently under 
preclinical as well as clinical trial studies to be considered in effective treatment of infec-
tious diseases. Quinoxaline compound 6, coded as BMS345541, is a kinase inhibitor which 
is utilized as an anti-tumor agent (82), while quinoxaline 7, coded as NVP-BSK805, is being 
developed as a valuable candidate for treating tumors and polycythemia (83) (Fig. 2).
Fig. 2. Some quinoxaline-based drugs and drug-like candidates as anticancer agents (ref. 83).
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NATURAL OCCURRENCE OF QUINOXALINES
Quinoxaline is the valuable core structure found in echinomycin (8), which is a natu-
rally occurring polypeptide antineoplastic antibiotic isolated from the bacterium Strepto-
myces echinatus. Echinomycin is known to be a strong inhibitor of RNA synthesis, which is 
attributed to its ability to bind to double-helical DNA. Echinomycin has also been isolated 
from Streptomyces lasalienis. It belongs to the family of quinoxaline antibiotics (84). There 
are interesting facts ascribable to this series of compounds due to the effective and efficient 
anticancer and antimicrobial activities they possess. Echinomycin biosynthesis, with the 
structure, as shown in Fig. 3, started with a molecule of quinoxaline-2-carboxylic acid (QC). 
l-tryptophan is the precursor of quinoxaline-2-carboxylic acid (QC) and its biosynthesis 
paralleled the first stage of nikkomycin biosynthesis (84). Quinoxaline is a benzopyrazine 
and this pyrazine ring system is found in the fungal metabolite aspergillic acid and in 
dihydro form in luciferin of several beetles including the firefly responsible for the chemi-
luminescence of this ostracod. Methoxypyrazine is a very important component of the 
aroma of many fruits and vegetables such as peas and Capsicum peppers, and also of wines 
(85). 
Synthesis of quinoxaline and its derivatives
(i) Condensation reaction of p-substituted benzyl with o-phenylene diamines was re-
ported to proceed readily and effectively using o-iodoxybenzoic acid (IBX) as catalyst at 25 
oC to furnish 2,3,6-trisubstituted quinoxaline derivative (9), as shown in Scheme 1 (86).
(ii) According to the previous findings from our laboratory, hydrazinolysis of quinoxa-
line-2,3-dione gave 3-hydrazinoquinoxalin-2(1H)-one (10), which subsequently underwent 
microwave-assisted reaction with indole-2,3-dione derivatives (isatin derivatives) to furnish 
Fig. 3. Naturally occurring quinoxaline-based antibiotic and anticancer agent echinomycin (8). 
Scheme 1
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the corresponding quinoxalinone hydrazones, 3-(2-(5-substituted-2-oxoindolin-3-ylidene)
hydrazinyl)quinoxalin-2(1H)-one (11) (in excellent yields at 400 W within 2 min). The micro-
wave assisted synthesis of isatin-based quinoxaline 11 is shown in Scheme 2 (13, 87).
(iii) In another study, microwave assisted reaction of 3-acetyl-2H-chromen-2-one de-
rivatives and cyclohexanone derivatives with the earlier prepared 3-hydrazinoquinoxaline 
(10) led to the formation of hydrazones 3-(2-(1-(6-substituted-2-oxo-2H-chromen-3-yl)ethy-
lidene)hydrazinyl)quinoxalin-2(1H)-one (12) and 3-(2-(2-substitutedcyclohexylidene) hy-
drazinyl)quinoxalin-2(1H)-one (13), resp., as expected. Formation of hydrazones 12 and 13 
is shown in Scheme 3 (88).
(iv) 3-Hydrazinoquinoxaline (10) was also used in earlier microwave assisted organic 
synthesis (MAOS) to validate its facile condensation with 1,3-diketone and β-keto ester to 
produce 3-(3,5-disubstituted-1H-pyrazol-1-yl)quinoxalin-2(1H)-one (14) and 3-(3-substitut-
ed-5-oxo-4,5-dihydro-1H-pyrazol-1-yl)quinoxalin-2(1H)-one (15), resp., as shown in 
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(v) Design of a method essential for the synthesis of a quinoxaline-based candidate via 
the one-pot approach using [2-(sulfooxy)ethyl]sulfuric acid (SESA) was achieved as shown 
in Scheme 5 (90). When benzil was used as a dicarbonyl synthon, 2,3-diphenyl quinoxaline 
(16) was obtained, whereas utilization of phenanthrene-9,10-dione as  dicarbonyl agent 
afforded dibenzo[a,c]phenazine (17) as shown in Scheme 5 (90).
ANTICANCER EFFICACY OF QUINOXALINES
Quinoxaline screened for various cancer treatments
Lung cancer. – From the class of quinoxaline scaffold screened against lung cancer cell 
lines, compound 18 exhibited promising activity as inhibitor of the Wnt/b-catenin signal route 
with IC50 of 0.905 nmol L–1 (91). The lung cancer cell HOP-92 showed no growth in the presence 
of compound 19 at 1.0 x 10–5 mol L–1 (92). Compound 20 was also documented to bring about 
growth inhibition in drug resistant cancerous cell lines of lung cancer (93) (Fig. 4).
Leukemia. – Series of quinoxalines were reported to show growth inhibitory activity 
against the leukemia cell lines HL-60 (with 75 % of GI50 values as low as 0.01 to 0.15 µmol L–1) 
(94).
However, compound 21 was the most active against the SR leukemia cell line with IC50 
< 0.01 µmol L–1 (94, 95). Compound 22, possessing 3,4,5-trimethoxyanilino pharmacophore 
Fig. 4. Selected quinoxalines with promising activity in lung cancer treatment.
Fig. 5. Selected quinoxalines with promising activity in leukemia treatment.
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at position 2 of the ring system, exhibited inhibition of leukemia cell lines HL-60 and 
MOLT-4 at nanomolar concentrations (95, 96). 2-Oxypropionic acid framework played a 
significant role in improving antitumor activity observed in quinoxaline template 23 
against the leukemia cell line HL-60 (96) (Fig. 5).
Colorectal cancer. – Compound 24 was highly potent against three colon cancer cell 
lines: HCT 116 p53+/+, HCT p53-/- and HT 29 with their respective IC50 of 0.40 ± 0.01, 
0.30 ± 0.07 and 0.30 ± 0.06 µmol L–1 (97). Tricyclic quinoxaline 25 was reported to inhibit 
the growth of LS174T colon cancer cells with IC50 of 4.12 ± 0.67 µmol L–1 and it was well 
tolerated without apparent side effects (98). Out of the library of quinoxaline derivatives, 
substituted dihydroquinozalin-2-one (26), synthesized from a copper-catalyzed coupling 
reaction, was the most potent with IC50 of 4.96 µmol L–1 against the HeLaS3 cancer cell line 
(99) (Fig. 6). 
Breast cancer. – Breast cancer is most common in mature female populations world-
wide (100). According to a study, the quinoxaline derivative 27 inhibited the growth of 
breast cancer neoplasms and over 50 tumor cell lines (101). Quinoxaline-1,4-dioxide 28 was 
reported to stop abnormal growth in breast cancer cell lines with enhanced efficacy (102). 
Compound 29 showed remarkable efficiency against the breast cancer cell line MCF-7 as 
well as in skin related carcinogenesis based on in vivo investigation in mice (103) (Fig. 7).
Liver cancer. – All newly synthesized compounds were investigated on the human 
liver cell line (HEPG2). Compound 30 emerged as the most potent of this series with IC50 
Fig. 6. Selected quinoxalines with promising activity in colorectal cancer treatment.
Fig. 7. Selected quinoxalines with promising activity in breast cancer treatment.
189
O. O. Ajani et al.: Chemistry and pharmacological diversity of quinoxaline motifs as anticancer agents, Acta Pharm. 69 (2019) 177–196.
 
of 4.29 µmol L–1 (104). Quinoxaline motif 31 was reported to be potent against HEPG2 at 
IC50 of 1.76 µmol L–1 (Fig. 8) according to a preliminary mechanism study (105). Degrees of 
dT-QX cytotoxicity, TYMP and TK1 proteins have been reported as good indicators of high 
anticancer activity of the thyme analogue of dT-QX, whose structure (32) is shown in Fig. 
9 (6). The result of the cell viability 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) assay on four human liver cell lines was as shown in Fig. 9b, wherein the 
liver cell line HL-7702 exhibited the highest % cell viability followed by Bel-7402 and the 
cell line with the lowest % cell viability in MTT assay was Hep3B. 
Fig. 8. Selected quinoxalines with promising activity in liver cancer treatment.
Fig. 9. Selected quinoxaline with promising activity in liver cancer treatment. Levels of dT-QX cyto-
toxicity and cellular TYMP and TK1 proteins in human liver cell lines. a) Chemical structure of 
thymidine analog dT-QX (32). b) Cell viability MTT assay on human liver cell lines including HL-
7702, Hep3B, HepG2, Bel-7402 and Bel-7404 after treatment of dT-QX at 50 µmol L–1 for 24 h (mean ± 
SEM, n = 3). c) Western blot analysis of TYMP and TK1 protein expression in HL-7702, Hep3B, HepG2, 
Bel-7402 and Bel-7404 liver cells (from ref. 6, with permission).
a)
 
b)                                                                   c)
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STRUCTURE-ACTIVITY RELATIONSHIP STUDY (SAR)
The versatile activities of quinoxaline 1,4-di-N-oxides (QdNOs) are closely related to 
their chemical structures. The two N-oxide groups in the quinoxaline ring are necessary for 
the antitumor potential (106). In 2-alkylcarbonyl-3-trifluoromethylquinoxaline-1,4-di-N-ox-
ide derivatives, anticancer activity depends on the substituents in the carbonyl group. It 
improves in the order: ethyl < isopropyl < tert-butyl < phenyl-ones (107). SAR studies for 
QdNOs suggest that position C(2) of quinoxaline should be substituted by electron-with-
drawing moieties, preferably by a nitrile or an aroyl, an ester, an N-substituted amide group 
or a short brominated alkyl chain, for enhanced anticancer activity (108). Position C(3) is 
most often substituted by a short alkyl chain (e.g., CH3, CF3) or phenyl. Substitution of C(6) 
or C(7) of QdNOs by Cl, F, CF3, or OCH3 is also advantageous in antitumor diversity (81).
CONCLUSIONS
Adverse effects and causes of cancer and tumor related diseases  are expatiated in the 
study. Quinoxalines have, indeed, brought about  considerable improvement and encour-
agement to human efforts in the fight against cancer. In addition, exploration of quinoxa-
line systems is unavoidable owing to their wide therapeutic applications. The present 
overview has revealed how quinoxaline and its derivatives have been used to inhibit the 
growth of cancer and tumor cells. Hence, due to the vast array of information gathered in 
the applications of quinoxaline in oncology, it is a warfare arsenal  that may be developed 
into therapeutically important new-generation anticancer agents and serve possible future 
drug discovery.
Acronyms. – ALL – acute lymphocytic leukemia, CQS – chloroquinoxaline sulfonamide, DNA – 
deoxyribonucleic acid, EMT – epithelial mesenchymal transition, HBV – hepatitis B virus, HCV – hep-
atitis C virus, IBX – o-iodoxybenzoic acid, IC – inhibitory concentration, MAOS – microwave assisted 
organic synthesis, MDR – multi-drug resistance, MTT – 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetra-
zolium bromide, NSCLC – non-small cell lung cancer, QdNOs – quinoxaline 1,4-di-N-oxides, QC – 
quinoxaline-2-carboxylic acid, RNA – ribonucleic acid, SAR – structure-activity relationship, SCLC – 
small cell lung cancer, TK1 – thymidine kinase 1, TYMP – thymidine phosphorylase, ZEB – zinc finger 
E-box binding homeobox
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